- Home
- NEA vs TLX Comparison
NEA vs TLX Comparison
Compare NEA & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEA | TLX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEA | TLX |
|---|---|---|
| Price | $11.23 | $10.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $21.13 |
| AVG Volume (30 Days) | ★ 724.6K | 146.1K |
| Earning Date | 01-01-0001 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.68 | $6.28 |
| 52 Week High | $11.90 | $14.27 |
Technical Indicators
Market Signals| Indicator | NEA | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 43.37 |
| Support Level | $11.04 | $10.12 |
| Resistance Level | $11.70 | $11.38 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 2.75 | 3.74 |
Price Performance
Historical ComparisonAbout NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.